# Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants

> **NCT01444781** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 1106 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Whooping Cough
- Hepatitis B
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide
- **BIOLOGICAL:** DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide
- **BIOLOGICAL:** DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine

## Key facts

- **NCT ID:** NCT01444781
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-04
- **Final completion:** 2013-10
- **Target enrollment:** 1106 (ACTUAL)
- **Last updated:** 2014-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01444781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01444781, "Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01444781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*